Previous research suggests that action language is comprehended by activating the motor system. We report a study, investigating a critical question in this research field: do negative sentences ...

Department of Bioscience and Biotechnology, Division of Bioresource and Bioenvironmental Sciences, Faculty of Agriculture, Graduate School, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka ...

Inhibitory synaptic potentials generated from single interneurons are sufficiently powerful to delay or entirely block the generation of action potentials in a large number of projection neurons ...

Depression, characterized by persistent sadness, hopelessness and a lack of interest in previously enjoyed activities, is one ...

The ACE inhibitor enalapril (20 mg once-daily ... Peak-to-trough ratios, used as an index of duration of action, ranged from 0.62 to 0.92 for aliskiren and 0.63 for irbesartan, indicating the ...

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseasesUnder regulatory review in the US, the EU, and China in ...

Influenza A virus envelop protein hemagglutinin (HA) plays important roles in viral entry. We previously have reported that MBX2546, a novel influenza A virus inhibitor, binds to HA and inhibits ...

U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , ...

Volastra Therapeutics has announced the preliminary data of its oral kinesin family member 18A (KIF18A) inhibitor, VLS-1488, ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed. Forced vital capacity ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...